Cargando…
Breakthrough SARS‐CoV‐2 infections in immune mediated disease patients undergoing B cell depleting therapy: A retrospective cohort analysis
OBJECTIVES: Patients with immune mediated inflammatory diseases (IMIDs) receiving B cell depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19 as well as the most likely to respond sub‐optimally to SARS‐CoV‐2 vaccines. However, little is known about the frequency or severity of b...
Autores principales: | Calabrese, Cassandra M, Kirchner, Elizabeth, Husni, Elaine M, Moss, Brandon P, Fernandez, Anthony P, Jin, Yuxuan, Calabrese, Leonard H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349969/ https://www.ncbi.nlm.nih.gov/pubmed/35791921 http://dx.doi.org/10.1002/art.42287 |
Ejemplares similares
-
Online, low-volume meditation does not alter immune-related biomarkers
por: Graham, Brett, et al.
Publicado: (2022) -
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity
por: Calabrese, Cassandra, et al.
Publicado: (2022) -
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review
por: Jones, Jessica M., et al.
Publicado: (2021) -
Identifying patients who will not reachieve remission after breakthrough seizures
por: Hughes, David M., et al.
Publicado: (2019) -
Influence of Deuterium-Depleted Water on the Isotope D/H Composition of Liver Tissue and Morphological Development of Rats at Different Periods of Ontogenesis
por: Alexandrovich Basov, Alexandr, et al.
Publicado: (2019)